BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38498191)

  • 1. Patterns of recurrence in HNSCC patients treated definitively with upfront surgery, chemoradiation.
    Fong PY; Loh TKS; Shen L; Eu DKC; Lim CM
    Eur Arch Otorhinolaryngol; 2024 May; 281(5):2645-2653. PubMed ID: 38498191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques.
    Leeman JE; Li JG; Pei X; Venigalla P; Zumsteg ZS; Katsoulakis E; Lupovitch E; McBride SM; Tsai CJ; Boyle JO; Roman BR; Morris LGT; Dunn LA; Sherman EJ; Lee NY; Riaz N
    JAMA Oncol; 2017 Nov; 3(11):1487-1494. PubMed ID: 28542679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Survival Outcomes Among Human Papillomavirus-Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy: An Observational Study.
    Kelly JR; Park HS; An Y; Contessa JN; Yarbrough WG; Burtness BA; Decker R; Husain Z
    JAMA Oncol; 2017 Aug; 3(8):1107-1111. PubMed ID: 28056116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Salvage Therapy for Oropharyngeal Cancer Recurrence Following Upfront Radiation Therapy and Prognostic Factors.
    Choi N; Kim HJ; Yi H; Kim H; Kim TH; Jeong HS; Son YI; Baek CH; Oh D; Ahn YC; Chung MK
    Cancer Res Treat; 2023 Oct; 55(4):1123-1133. PubMed ID: 37157954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma.
    Howard J; Masterson L; Dwivedi RC; Riffat F; Benson R; Jefferies S; Jani P; Tysome JR; Nutting C
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD010963. PubMed ID: 27943254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of timing and patterns of treatment failure, and survival outcomes after progression between HPV+ and HPV- patients undergoing chemoradiation for oropharyngeal squamous cell carcinomas.
    Laxague F; Zeng PYF; Zabihi D; Fnais N; Alshahrani M; Fung K; MacNeil D; Mendez A; Yoo J; Mymryk JS; Barrett JW; Palma DA; Nichols AC
    Head Neck; 2024 Mar; 46(3):503-512. PubMed ID: 38100227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
    Adkins D; Ley J; Michel L; Wildes TM; Thorstad W; Gay HA; Daly M; Rich J; Paniello R; Uppaluri R; Jackson R; Trinkaus K; Nussenbaum B
    Oral Oncol; 2016 Oct; 61():1-7. PubMed ID: 27688097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma.
    Oguejiofor KK; Hall JS; Mani N; Douglas C; Slevin NJ; Homer J; Hall G; West CM
    Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):630-8. PubMed ID: 23916365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
    Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
    Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
    Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
    Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer.
    Mehanna H; McConkey CC; Rahman JK; Wong WL; Smith AF; Nutting C; Hartley AG; Hall P; Hulme C; Patel DK; Zeidler SV; Robinson M; Sanghera B; Fresco L; Dunn JA
    Health Technol Assess; 2017 Apr; 21(17):1-122. PubMed ID: 28409743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS.
    Carey RM; Brody RM; Shimunov D; Shinn JR; Mady LJ; Rajasekaran K; Cannady SB; Lin A; Lukens JN; Bauml JM; Cohen RB; Basu D; O'Malley BW; Weinstein GS; Newman JG
    Laryngoscope; 2021 Dec; 131(12):E2865-E2873. PubMed ID: 34076275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival outcomes for head and neck cancer patients with N3 cervical nodal metastases.
    Virk JS; Ingle M; Podesta CM; Gujral DM; Awad Z
    Clin Otolaryngol; 2020 May; 45(3):342-349. PubMed ID: 31869000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Rosen BS; Wilkie JR; Sun Y; Ibrahim M; Casper KA; Miller JE; Chotchutipan T; Stucken CL; Bradford C; Prince MEP; Rosko AJ; Malloy KM; McLean SA; Chinn SB; Shuman AG; Spector ME; Swiecicki PL; Worden FP; Shah JL; Schonewolf CA; Chapman CH; Eisbruch A; Mierzwa ML
    Radiother Oncol; 2021 Feb; 155():174-181. PubMed ID: 33069764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of salvage surgery for recurrent or residual head and neck squamous cell carcinoma.
    Maruo T; Zenda S; Shinozaki T; Tomioka T; Okano W; Sakuraba M; Tahara M; Hayashi R
    Jpn J Clin Oncol; 2020 Mar; 50(3):288-295. PubMed ID: 31845736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant Chemoradiation After Surgical Resection in Elderly Patients With High-Risk Squamous Cell Carcinoma of the Head and Neck: A National Cancer Database Analysis.
    Woody NM; Ward MC; Koyfman SA; Reddy CA; Geiger J; Joshi N; Burkey B; Scharpf J; Lamarre E; Prendes B; Adelstein DJ
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):784-792. PubMed ID: 28602410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Patients With Single-Node Metastasis of Human Papillomavirus-Related Oropharyngeal Cancer Treated With Transoral Surgery.
    Chen SY; Sinha P; Last A; Ettyreddy A; Kallogjeri D; Pipkorn P; Rich JT; Zevallos JP; Paniello R; Puram SV; Van Abel K; Moore EJ; Oppelt P; Palka K; Adkins D; Daly M; Gay H; Thorstad WL; Jackson RS
    JAMA Otolaryngol Head Neck Surg; 2021 Jan; 147(1):16-22. PubMed ID: 33151273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in Functional and Survival Outcomes Between Patients Receiving Primary Surgery vs Chemoradiation Therapy for Treatment of T1-T2 Oropharyngeal Squamous Cell Carcinoma.
    Amin DR; Philips R; Bertoni DG; Mastrolonardo EV; Campbell DJ; Agarwal AM; Tekumalla S; Urdang ZD; Luginbuhl AJ; Cognetti DM; Curry JM
    JAMA Otolaryngol Head Neck Surg; 2023 Nov; 149(11):980-986. PubMed ID: 37422846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cycle induction chemotherapy before chemoradiotherapy or surgery in functionally inoperable head and neck squamous cell carcinoma: 10-year results.
    Breheret M; Lubgan D; Haderlein M; Hecht M; Traxdorf M; Schmidt D; Müller S; Kitzsteiner C; Kuwert T; Iro H; Fietkau R; Semrau S
    Eur Arch Otorhinolaryngol; 2020 Jan; 277(1):245-254. PubMed ID: 31583430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
    Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
    Trials; 2014 Nov; 15():469. PubMed ID: 25432788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.